

## **Johannes Oldenburg, Prof. Dr. med.**

\*15.12.1960, German, male

### **Academic Qualifications**

2005-present	Full Professor, Director of the Institute of Experimental Haematology and Transfusion Medicine, University Clinic Bonn, Germany
1998	Postdoctoral-lecture qualification, University of Würzburg, Germany
1992	Doctorate, Dr. med., University of Bonn, Germany

### **Postgraduate Professional Career**

2007	Specialization in Medical Genetics
2005	Specialization in Haemostaseology
2001-2005	Assistant Professor, Institute of Transfusion Medicine and Immune Haematology, Frankfurt, Germany
2000-2001	Assistant Professor, Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Germany
1995-2000	Postdoctoral research fellow of the Foundation "Haemotherapy-Research" at the Institute of Human Genetics, University of Würzburg,
1997	Qualification as Specialist of Transfusion Medicine
1989-1995	Training physician, Institute of Experimental Haematology and Transfusion Medicine, University of Bonn, Germany

### **Scientific Activities, Honors and Awards**

Since 2019	President, German Society of Thrombosis and Haemostasis (GTH)
2017	President of the ISTH Congress in Berlin (9500 participants)
2015-2019	Member of the ISTH-Council
2004-2012	Board member of the GTH.
2011	President of the GTH Congress in Wiesbaden.
2009-2013	Board member of the DGTI
2009-2013	Board member of the European Association for Haemophilia and Allied Disorders
2007	ISTH-Investigator Recognition Award
2007	ISTH Shirley Johnson Memorial Plenary Lecture
2005	Paul Martini Award
2002	Alexander Schmidt Award of the GTH
Since 1995	Member of the 'Arbeitskreis Blut' at the German Health Ministry

### **Five selected recent publications (from > 500 in PubMed)**

1. Shapiro AD, Angchaisuksiri P, Astermark J, Benson G, Castaman G, ..., Young G, Zupancic-Salek S, **Oldenburg J.** Subcutaneous conzizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors:phase 2 trial results. *Blood.* 2019;134(22):1973-1982.
2. **Oldenburg J.** Mahlangu JN, Kim B, Schmitt C, ..., Asikanius E, Levy GG, Windyga J, Shima M. Emicizumab Prophylaxis in Hemophilia A with inhibitors. *N Engl J Med.* 2017;377(9): 809-818.
3. Czogalla KJ, Biswas A, Höning K, Hornung V, Liphardt K, Watzka M, **Oldenburg J.** Warfarin and vitamin K compete for binding to Phe55 in human VKOR. *Nat Struct Mol Biol.* 2017;24(1):77-85
4. Yadegari H, Biswas A, Akhter MS, Driesen J, Ivaskevicius V, Marquardt N, **Oldenburg J.** Intron retention resulting from a silent mutation in the VWF gene that structurally influences the 5' splice site. *Blood.* 2016;128(17):2144-2152.
5. **Oldenburg J.** Optimal treatment strategies for hemophilia:achievements and limitations of current prophylaxis. *Blood.* 2015;125(13):2038-44.